| Laura Michaud, | |
|
8800 N Tryon St, Charlotte, NC 28262-3300 | |
| (704) 863-6241 | |
| Not Available |
| Full Name | Laura Michaud |
|---|---|
| Gender | Female |
| Speciality | Hospitalist |
| Location | 8800 N Tryon St, Charlotte, North Carolina |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295955805 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 2009-01214 (North Carolina) | Primary |
| Entity Name | Carolinas Physicians Network Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477878890 PECOS PAC ID: 3375449655 Enrollment ID: O20031219000455 |
News Archive
Ornaments glistening on a pine tree, carols filling the air, shoppers scurrying through stores and the smell of goodies baking in the oven—it's the holidays. For many this truly is the most wonderful time of the year. Still, for those who have lost a loved one, the empty chair at the table or one less present under the tree can be a painful reminder of the one who is missing.
Smokers who receive telephone care and counseling for smoking cessation have higher rates of stopping smoking than those who receive routine care by health care providers, according to a study in the March 13 issue of Archives of Internal Medicine.
The Melanoma Network of Canada is pleased that the Canadian regulatory body, pCODR (pan-Canadian Oncology Drug Review) has made an initial recommendation that includes positive clinical evaluations for the latest treatments for metastatic melanoma.
ITL BioMedical, a division of ITL that sets industry standards for the innovative design and production of biological sampling systems for human and animal use, is pleased to announce that after launching its highly innovative patented DonorCare Needle Guard 2 mid-October the Company has already achieved significant sales in excess of one million products.
Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 2a clinical trial that will evaluate multiple combinations of VX-770 and VX-809, investigational oral cystic fibrosis transmembrane conductance regulator (CFTR) modulators for the treatment of cystic fibrosis (CF). The trial is designed to evaluate the safety and tolerability of VX-809 dosed alone for 14 days followed by dosing of VX-809 in combination with VX-770 for 7 days.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Laura Michaud, 8800 N Tryon St, Charlotte, NC 28262-3300 Ph: () - | Laura Michaud, 8800 N Tryon St, Charlotte, NC 28262-3300 Ph: (704) 863-6241 |
News Archive
Ornaments glistening on a pine tree, carols filling the air, shoppers scurrying through stores and the smell of goodies baking in the oven—it's the holidays. For many this truly is the most wonderful time of the year. Still, for those who have lost a loved one, the empty chair at the table or one less present under the tree can be a painful reminder of the one who is missing.
Smokers who receive telephone care and counseling for smoking cessation have higher rates of stopping smoking than those who receive routine care by health care providers, according to a study in the March 13 issue of Archives of Internal Medicine.
The Melanoma Network of Canada is pleased that the Canadian regulatory body, pCODR (pan-Canadian Oncology Drug Review) has made an initial recommendation that includes positive clinical evaluations for the latest treatments for metastatic melanoma.
ITL BioMedical, a division of ITL that sets industry standards for the innovative design and production of biological sampling systems for human and animal use, is pleased to announce that after launching its highly innovative patented DonorCare Needle Guard 2 mid-October the Company has already achieved significant sales in excess of one million products.
Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 2a clinical trial that will evaluate multiple combinations of VX-770 and VX-809, investigational oral cystic fibrosis transmembrane conductance regulator (CFTR) modulators for the treatment of cystic fibrosis (CF). The trial is designed to evaluate the safety and tolerability of VX-809 dosed alone for 14 days followed by dosing of VX-809 in combination with VX-770 for 7 days.
› Verified 9 days ago
Shakuntala Mathapati, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1000 Blythe Blvd, Charlotte, NC 28203 Phone: 704-355-0720 | |
Nicole A. Cagle Richardson, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 1001 Blythe Blvd, Medical Center Plaza Suite 200, Charlotte, NC 28203 Phone: 704-381-8840 | |
David Jerret Pubantz, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 4501 Cameron Valley Pkwy, Ste 200-b, Charlotte, NC 28211 Phone: 704-381-0500 | |
Joshua Lee Eichenberger, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1000 Blythe Blvd, Charlotte, NC 28203 Phone: 704-355-0720 | |
Stefanie Rose Reed, DO Hospitalist Medicare: Medicare Enrolled Practice Location: 1001 Blythe Blvd, Medical Center Plaza Suite 200, Charlotte, NC 28203 Phone: 704-381-8840 | |
Jasdip G. Bajaj, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 8800 N Tryon St, Charlotte, NC 28262 Phone: 704-863-6241 | |
Thanigaiarsu Thiyagarajan, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1100 Blythe Blvd, Charlotte, NC 28203 Phone: 704-355-4475 |